Zr89MonoclonalAntibodyLabelingQC

Zr-89 Monoclonal Antibody Labeling QC — Quality control of Zr-89 labeled monoclonal antibodies

ℹ️ Utility checks critical parameters of Zr-89 mAbs:

• Radiochemical purity (≥95%)
• Free zirconium (≤2%)
• Immunoreactivity (≥90%)
• Y-88 impurity (<0.001%) — CRITICAL!

⚠️ CRITICAL: Y-88 (T½=106 days) creates long-term radiation burden!

Zr-89 is used for immuno-PET (visualization of antigen expression).

Preservation of antibody structure is critical for binding specificity.

Usage

Zr89MonoclonalAntibodyLabelingQC.exe → demo mode (console output)

Zr89MonoclonalAntibodyLabelingQC.exe input.csv output.json → evaluate your data

Input format

BatchNumber,AntibodyName,RadiochemicalPurityPercent,FreeZirconiumPercent,AggregatesPercent,SpecificActivityMBq_per_mg,ImmunoreactivityPercent,pH,EndotoxinsEU_per_mL,SterilityTest,ActivityMBq,RadionuclidicPurityPercent,Y88ImpurityPercent

Example

ZR89-TRASTUZUMAB-2026-001,Trastuzumab,98.0,1.0,0.5,150.0,95.0,7.0,5.0,0,200.0,99.95,0.0005

— WHY IS THIS NEEDED?

Zr-89 labeled monoclonal antibodies are powerful tool for immuno-PET.

• Allow visualization of biopharmaceutical distribution in body (pharmacokinetics).
• Zr-89 has 78.4-hour half-life, ideally matching antibody circulation time.
• Requires use of chelators (e.g., DFO) for strong binding.
• Critical to preserve immunological activity of antibody after labeling.

⚠️ CRITICAL:

• Radiochemical purity ≥95% — guarantee that signal comes from antibody, not free metal.
• Free zirconium ≤2% — free Zr accumulates in bones, masking metastases.
• Immunoreactivity ≥90% — antibody must recognize its target.
• Aggregates <2% — aggregated antibodies are rapidly cleared by liver and may cause reaction.
• Y-88 impurity <0.001% — Y-88 is byproduct of production and has long half-life.
• Specific activity must be optimized to balance between signal and stability.
• pH 6.5-7.5 — physiological range, critical for protein stability.
• Endotoxins <175 EU/mL — standard for parenteral drugs.
• Sterility — MANDATORY.

Key features

• Assessment of immunoreactivity (IR), unique for protein drugs.
• Control of protein aggregation, critical for safety.
• Strict control of Y-88 impurity.
• Specific activity check for balance between signal and stability.
• Compliance with GMP requirements for antibody-based radiopharmaceuticals.

Critical parameters

• Radiochemical purity: ≥95.0%
• Free zirconium: ≤2.0%
• Protein aggregates: <2.0%
• Immunoreactivity: ≥90.0%
• Specific activity: ≥50.0 MBq/mg
• Radionuclidic purity: ≥99.9%
• Y-88 impurity: <0.001%
• pH: 6.5–7.5
• Endotoxins: <175 EU/mL
• Sterility: no growth

💡 Usage tips:

1. Radiochemical purity determined by SEC-HPLC (size exclusion chromatography).

2. Immunoreactivity checked using ELISA or cell binding assays.

3. Aggregation controlled by SEC or DLS.

4. Drug should be stored at 4°C and protected from light.

5. Zr-89 emits positrons and gamma quanta, requiring protection during handling.

⚠️ Note: Zr-89 mAbs represent pinnacle of personalized medicine, allowing to check if drug reaches tumor in specific patient before starting expensive therapy. Quality control here is more complex than for small molecules as it requires assessment of biological function of protein.